Genital Herpes Vaccine Partially Successful
Results of a clinical trial show that an investigational vaccine for genital herpes protected some women against infection from one of the two strains of virus that cause the disease. Although the results show only partial success, the researchers who conducted the trial believe they represent progress towards a genital herpes vaccine. They write about their findings in the 5 January online issue of the New England Journal of Medicine. There is currently no cure or approved vaccine for genital herpes, a sexually transmitted disease caused by the viruses herpes simplex type 1 (HSV-1) and herpes simplex type 2 (HSV-2), with most infections thought to be caused by the latter (although a surprising finding of this study suggests that could be changing).
Human Trials Initiated For New HIV Vaccine
In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the Infectious Disease Research Institute (IDRI) have come together to evaluate whether the vaccine is safe for use in human volunteers.
Office-Based Action The Best Way To Boost Adult Immunizations
Promoting immunizations as a part of routine office-based medical practice is needed to improve adult vaccination rates, a highly effective way to curb the spread of diseases across communities, prevent needless illness and deaths, and lower health care costs, according to a new RAND Corporation study. Increasingly, vaccinations are being offered outside of physician offices at pharmacies, workplaces and retail medical clinics. Even so, office-based medical practice continues to be central to the delivery of recommended vaccinations to adults.